Azurix, 120 mg 30 pcs

Uric acid is the end product of purine metabolism in humans and is formed by the following reaction: hypoxanthine → xanthine → uric acid. Xanthine oxidase is a catalyst for both steps of this reaction. Febuxostat is a 2-arylthiazole derivative. Its therapeutic effect is associated with reduction of serum uric acid concentration by selective inhibition of xanthine oxidase. Febuxostat is a potent and selective non-purine xanthine oxidase inhibitor (NP-SIXO), its inhibition constant (Ki) is <1 nM. Febuxostat was shown to significantly inhibit the activity of both oxidized and reduced forms of xanthine oxidase. At therapeutic concentrations, febuxostat does not affect other enzymes involved in purine or pyrimidine metabolism, such as guanine deaminase, hypoxanthineguanine phosphoribosyltransferase, orotidine monophosphate decarboxylase or purine nucleoside phosphorylase.Clinical effectiveness and safety:

Indications

Active ingredient

How to take, the dosage

Interaction

Contraindications

Side effects

Overdose

Similarities